| Metric | Current Period | Prior Year Same Period | YoY |
|---|---|---|---|
| Revenue / Net Sales | ¥112.1B | ¥118.3B | -5.2% |
| Operating Income / Operating Profit | ¥10.0B | ¥16.8B | -40.3% |
| Ordinary Income | ¥10.4B | ¥17.0B | -39.1% |
| Net Income / Net Profit | ¥7.2B | ¥11.5B | -37.0% |
| ROE | 9.0% | 14.6% | - |
For the fiscal year ending February 2026, the Q2 cumulative results landed at Revenue ¥112.1B (YoY -¥6.2B, -5.2%), Operating Income ¥10.0B (YoY -¥6.8B, -40.3%), Ordinary Income ¥10.4B (YoY -¥6.6B, -39.1%), and Net Income attributable to owners of the parent ¥7.2B (YoY -¥4.3B, -37.0%), representing revenue decline and a substantial profit decline. Gross margin was 75.7%, broadly flat from 75.8% in the prior-year period, but SG&A ratio rose to 66.8% (prior-year period 61.7%), up 5.1ppt, driving operating margin down to 8.9% (prior-year period 14.2%), a sharp 5.3ppt decline. Non-operating income was minor at ¥0.4B, so deterioration in core operations directly pressured net profit. EPS was ¥4.99 (prior-year period ¥8.66, -42.4%), reflecting the decline in net income.
[Revenue] Revenue of ¥112.1B was down ¥6.2B YoY (-5.2%). As a single-segment company (Health & Beauty Care related business), segmental breakdowns are not disclosed in detail, but company materials suggest shipment adjustments of key products and a pause in demand. Cost of sales declined to ¥27.3B (prior ¥28.6B, -4.5%), compressing more than the revenue drop, resulting in gross profit of ¥84.8B (prior ¥89.7B, -5.4%) and gross margin of 75.7% (prior period 75.8%), largely maintained. Cost structure appears intact; top-line decline is presumed to be driven mainly by volume and price factors.
[Profitability] SG&A was ¥74.8B (prior period ¥72.9B, +2.6%), increasing despite lower revenue, raising the SG&A ratio to 66.8% (prior period 61.7%), up 5.1ppt. Increases in customer acquisition costs such as advertising and logistics, and higher personnel expenses reversed operating leverage, resulting in Operating Income of ¥10.0B (prior ¥16.8B, -40.3%). Operating margin deteriorated to 8.9% (prior period 14.2%), down 5.3ppt. Non-operating income was ¥0.4B (including interest income ¥0.1B, insurance income ¥0.1B), non-operating expenses ¥0.0B, leaving Ordinary Income at ¥10.4B (-39.1%). Extraordinary losses were ¥0.0B and negligible. Pre-tax income of ¥10.4B less income taxes ¥3.4B (effective tax rate 32.8%) resulted in Net Income ¥7.2B (-37.0%). Non-controlling interests were ¥0.0B and negligible; Net Income attributable to owners of the parent was ¥7.0B (prior ¥12.1B, -42.3%). Comprehensive income of ¥7.0B was nearly identical to net income, indicating no marked valuation differences. In conclusion, revenue decline combined with a higher SG&A ratio produced a large profit contraction.
[Profitability] Operating margin 8.9% (prior period 14.2%), Net margin 6.5% (prior period 10.2%) — both deteriorated. ROE 9.0% (prior period 16.2%) decreased by 7.2ppt, driven mainly by lower net margin and a slight decline in total asset turnover. Gross margin 75.7% was maintained, but SG&A ratio increase to 66.8% (+5.1ppt) reversed operating leverage. [Cash Quality] Operating Cash Flow (OCF) was ¥8.5B, 1.18x Net Income ¥7.2B, which is healthy. Adding depreciation ¥0.5B and goodwill amortization ¥0.8B yields EBITDA of approximately ¥10.5B (EBITDA margin 9.4%), and OCF/EBITDA at 0.81x indicates somewhat weak cash conversion. Free Cash Flow was ¥5.5B (OCF ¥8.5B - Investing CF ¥3.0B), roughly covering total dividends ¥5.4B. [Investment Efficiency] Total asset turnover annualized 1.18x, inventory days (DIO) 184 days indicating high inventory levels; DSO 30 days, DPO 57 days, resulting in cash conversion cycle (CCC) 157 days and prolonged working capital tie-up. CapEx ¥0.0B is well below depreciation ¥0.5B, showing marked investment restraint. [Financial Soundness] Equity ratio 84.8% (prior period 85.9%) remains very high. Cash and deposits ¥57.0B versus current liabilities ¥13.9B yield current ratio 585% and quick ratio 508%, indicating solid short-term liquidity. Interest-bearing debt is limited to lease liabilities — effectively debt-free. Debt-to-equity ratio 0.18x and interest coverage 2,762x indicate minimal financial risk. Goodwill ¥2.9B represents 3.6% of shareholders’ equity ¥80.5B and is limited.
OCF was ¥8.5B (prior period ¥18.1B, -53.4%), halving year-on-year. Starting from pre-tax profit ¥10.4B, adding non-cash expenses such as depreciation ¥0.5B and goodwill amortization ¥0.8B gives a subtotal of ¥13.0B (prior period ¥25.4B). Changes in working capital absorbed cash: inventory increase -¥1.3B (prior period decrease +¥3.2B), trade receivables increase +¥0.8B (prior period decrease +¥2.2B), trade payables increase +¥0.6B (prior period +¥1.2B). After tax payments -¥4.6B (prior -¥7.3B), OCF settled at ¥8.5B. Worsening working capital driven by elevated inventory and higher receivables reduced cash conversion efficiency. Investing CF was -¥3.0B, mainly acquisition of subsidiary shares -¥2.7B (one new consolidated subsidiary), and tangible fixed asset additions -¥0.0B, indicating minimal CapEx. Financing CF was -¥5.4B, primarily dividend payments -¥5.4B (prior -¥3.6B); buybacks were -¥0.0B and negligible. Cash and cash equivalents rose slightly from ¥56.2B at the beginning of the period to ¥57.0B (+¥0.3B), reflecting limited net change and the impact of halved OCF. Free Cash Flow ¥5.5B covers dividends but leaves little buffer; inventory reduction and improving working capital efficiency are key to restoring cash generation capacity over the medium term.
Of Operating Income ¥10.0B, the majority is recurring core business income. Non-operating income ¥0.4B (interest income ¥0.1B, insurance income ¥0.1B) and foreign exchange gains ¥0.0B are minor. Non-operating expenses ¥0.0B and interest expenses ¥0.0B are effectively negligible. Extraordinary losses ¥0.0B indicate no one-off impacts. Therefore, the gap between Ordinary Income ¥10.4B and Operating Income ¥10.0B is only ¥0.4B, and earnings are largely recurring. Net Income ¥7.2B results from deducting income taxes ¥3.4B from Ordinary Income, with non-controlling interests ¥0.0B negligible. Comprehensive income ¥7.0B aligns with net income, indicating no valuation swing. OCF ¥8.5B is 1.18x Net Income ¥7.2B, showing cash-backed profit generation. However, OCF/EBITDA at 0.81x and working capital deterioration (inventory increase -¥1.3B, receivables increase +¥0.8B) have tightened cash. CapEx ¥0.0B versus depreciation ¥0.5B signals underinvestment, raising concerns about sustaining future earnings capacity. Goodwill amortization ¥0.8B is a non-cash expense under JGAAP, but limited in scale. Overall, ordinary earnings quality is high, but worsening working capital management partially offsets that quality.
Full-year forecast: Revenue ¥159.6B (YoY +42.4%), Operating Income ¥10.6B (+5.9%), Ordinary Income ¥10.8B (+4.2%), Net Income ¥7.2B (+0.0%). Q2 cumulative results represent 70.2% of full-year Revenue forecast (¥112.1B/¥159.6B), 94.3% of Operating Income (¥10.0B/¥10.6B), 96.3% of Ordinary Income (¥10.4B/¥10.8B), and 100.0% of Net Income (¥7.2B/¥7.2B), indicating that while revenue assumes a significant back-half ramp, profits have largely been achieved for the full year. Back-half weighted revenue suggests seasonality or new product launches, but full-year operating margin is assumed at 6.6% (¥10.6B/¥159.6B), below the Q2 cumulative 8.9%, implying higher SG&A in H2 is factored in. Given Net Income has already reached the full-year forecast, upside in H2 is limited. Dividend forecast is ¥1.70 per share annually (¥1.70 in Q2), implying a payout ratio of 32.3% relative to full-year EPS forecast ¥5.26. Based on progress, revenue requires substantial acceleration in H2 while profit targets are mostly achieved; cost-efficiency and working capital management in H2 are the focal points for plan execution.
Q2 dividend was ¥1.70, up ¥0.40 from prior-year Q2 ¥1.30. Full-year dividend forecast remains ¥1.70 (no further increase). Dividend payout ratio relative to Q2 cumulative EPS ¥4.99 is 68.1% (3.5/5.14, annualized) — high. Dividend payout ratio relative to full-year EPS forecast ¥5.26 is 32.3% (¥1.70/¥5.26) — low, but this reflects that full-year net income forecast equals the Q2 cumulative results and does not embed H2 profit growth. Practically, payout ratio should be assessed on the Q2 results basis at 68.1%; Free Cash Flow ¥5.5B vs. total dividends ¥5.4B (annualized based on Q2 cumulative) yields a dividend coverage of 1.02x, leaving limited buffer. Cash of ¥57.0B is ample, supporting short-term dividend sustainability, but with OCF down 53.4% YoY and worsening inventory and working capital reducing cash generation, maintaining a high payout ratio may constrain medium-term capital allocation flexibility. Share buybacks were ¥0.0B and not executed; total shareholder return is dividends only. The payout ratio of 68.1% materially exceeds industry benchmarks (manufacturing typical 30–50%), posing a challenge to balancing dividends and growth investment.
Deterioration of profitability due to higher SG&A ratio: SG&A ratio rose to 66.8% (prior period 61.7%), up 5.1ppt, driving operating margin down to 8.9% (prior period 14.2%), a 5.3ppt decline. Increases in advertising and logistics costs appear to be the main causes; sustained high customer acquisition costs or intensified promotions to stimulate demand will pressure profits. If SG&A continues to increase by +2.6% despite declining revenue, achieving the full-year operating margin target of 6.6% (company guidance) may become difficult.
Excess inventory and deteriorating working capital efficiency: Inventory ¥10.7B (prior period ¥11.3B, -5.0%) has not compressed in line with revenue decline, resulting in DIO 184 days and extended CCC 157 days, which contributed to OCF halving to ¥8.5B (prior period ¥18.1B, -53.4%). Risks include inventory write-downs and discounting; continued deterioration in cash conversion efficiency would constrain dividend resources and growth investment capacity.
Underinvestment risking medium- to long-term competitiveness: CapEx ¥0.0B is far below depreciation ¥0.5B, with CapEx/Depreciation at 0.03x — extremely low. Intangible assets rose to ¥3.7B following subsidiary acquisition, but internal R&D and equipment renewal are restrained. In a single-segment (H&B care) business, insufficient investment to maintain or improve product development and production efficiency could erode the future earnings base.
Profitability & Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 8.9% | 7.8% (4.6%–12.3%) | +1.2pt |
| Net Margin | 6.5% | 5.2% (2.3%–8.2%) | +1.3pt |
Profitability metrics exceed industry medians, supported by high gross margin of 75.7%, but YoY declines in operating margin (-5.3ppt) and net margin (-3.7ppt) have narrowed the company’s relative advantage.
Growth & Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth (YoY) | -5.2% | 3.7% (-0.4%–9.3%) | -8.9pt |
Revenue growth lags the industry median by 8.9ppt, indicating the company is in a revenue contraction phase. The company forecasts +42.4% for the full year, but the Q2 cumulative results assume substantial H2 acceleration.
※ Source: Company compilation
Restoring cost efficiency is the top priority. The structural impact of a 5.1ppt rise in SG&A ratio reducing operating margin by 5.3ppt suggests lowered advertising ROI or higher logistics costs. Full-year guidance assumes operating margin 6.6%, below the Q2 cumulative 8.9%, so H2 cost control is critical. Inventory compression and improved advertising efficiency to normalize SG&A ratio would be catalysts for earnings recovery.
Deterioration in working capital management is impeding cash generation. With DIO 184 days and CCC 157 days, OCF declined 53.4% YoY. A practical payout ratio of 68.1% with Free Cash Flow ¥5.5B barely covering dividends ¥5.4B is unsustainable without inventory correction. Improving inventory turns and shortening CCC are prerequisites for securing medium-term dividend capacity and resuming growth investment.
Post-M&A integration effects will be key from H2 onward. One new consolidated subsidiary (acquisition of subsidiary shares ¥2.7B) produced goodwill ¥2.9B, which is 3.6% of net assets and modest; amortization burden is limited at ¥0.8B/year. If integration synergies (expanded product lineup, shared sales channels) materialize, achieving both the full-year Revenue +42.4% and improved cost efficiency is feasible; integration delays would increase the risk of missing targets.
This report is an earnings analysis document automatically generated by AI analyzing XBRL disclosure data. It does not constitute a recommendation to invest in any specific security. Industry benchmarks are compiled by the Company based on public financial statements and provided as reference information. Investment decisions are your responsibility; consult a professional advisor as needed before making any investment decision.
---End of Report---